Skip to main content

Clear Cell Renal Cell Cancer Clinical Trials

Review the clear cell renal cell cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-50 of 66

Molecular Residual Disease-Guided Treatment of Renal Cell Carcinoma, MRD GATE RCC Trial
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
A Dendritic Cell Vaccine in Combination with Cabozantinib for Altering the Immune System in Patients with Localized Clear Cell Renal Cell Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
STING Agonist (IMSA101) and Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy with Nivolumab for the Treatment of Stage IV Renal Cell Carcinoma in Patients who Progressed on Immunotherapy, SPARK Trial
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Olaparib for Treatment of Metastatic Kidney Cancer in Patients with DNA Repair Gene Mutations, the ORCHID Study
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Belzutifan versus Active Surveillance for the Treatment of Metastatic Clear Cell Renal Cell Cancer, BRAVE-ROC Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Belzutifan or Pembrolizumab Alone versus in Combination for Neoadjuvant Treatment of Clear Cell Renal Cell Cancer, BLAZE Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Neoadjuvant Zanzalintinib Plus Nivolumab for the Treatment of Locally Advanced and/or Inoperable Clear Cell Renal Cell Cancer, EXPLORE-RCC Trial
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Ivonescimab for the Treatment of Previously Treated Metastatic/Advanced Clear Cell Renal Cell Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Inulin Gel in Combination with Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
177Lu Girentuximab in Combination with Cabozantinib and Nivolumab for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
CD70 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells and Lymphodepleting Chemotherapy for the Treatment of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Evaluating the Impact of Cabozantinib with Nivolumab on the Bone Immune Microenvironment in Treating Metastatic Clear Cell Renal Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Immunotherapy (Nivolumab and Ipilimumab) with and without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer
Status: Active
Location: 2 locations
Nivolumab and Ipilimumab with and without Camu Camu for the Treatment of Patients with Metastatic Renal Cell Carcinoma
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Genetically Engineered Cells (TGFβR-2 KO CD70 CAR NK Cell Therapy) with Lymphodepleting Chemotherapy for the Treatment of Unresectable or Metastatic Refractory Clear Cell Renal Cell Carcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Status: Active
Location: See ClinicalTrials.gov
A Study of PSB205 in Subjects With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov